Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans
Greetje J. de Grooth(Radboud University Nijmegen), John J.P. Kastelein(QRx Pharma (United States)), Aeilko H. Zwinderman(Amsterdam Neuroscience), Jan L. Posma(Radboud University Nijmegen), Anton F. H. Stalenhoef(Translational Therapeutics (United States)), Jacqueline de Graaf(Radboud University Nijmegen), Arie van Tol(Radboud University Nijmegen), Jan Albert Kuivenhoven(University Medical Center Groningen)
Cited by 455
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews
|Journal of Clinical Epidemiology|2005|3.3k
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
|European Heart Journal|2013|2.7k
Lipoprotein(a) as a cardiovascular risk factor: current status
|European Heart Journal|2010|1.8k